deltatrials
Completed PHASE1 NCT00001736

New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis

Safety and Efficacy Trial of a Proposed NDA Formulation of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis

Sponsor: National Eye Institute (NEI)

Conditions Cystinosis
Interventions Cysteamine
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: May 31, 1998 Completion: Mar 31, 2001

Listed as NCT00001736, this PHASE1 trial focuses on Cystinosis and remains completed. Sponsored by National Eye Institute (NEI), it has been updated 5 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

May 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Eye Institute (NEI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States